Who
Martin Babler
Director
Company insider
Files Form 4 as: Director, MapLight Therapeutics; Director, Prelude Therapeutics; President, CEO and Chairman, Alumis; Director, 89bio; Director, Neurogene; President, CEO, Principia Biopharma; Director, ZS Pharma; Director, Infinity Pharmaceuticals.
In numbers
- Trades disclosed
- 108
- Buys
- 1
- Sells
- 4
- Bought
- $101K
- Sold
- $3.4M
- Companies
- 8
- Companies where not an officer
- 6
- First trade
- 22 May 2008
- Last trade
- 23 Jun 2026
- Last filed
- 25 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jun 2026filed 25 Jun 2026 | MPLT MapLight TherapeuticsBiotechnology | SEC FORM 4 Code A | —7,864 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | MPLT MapLight Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,804 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | MPLT MapLight Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,804 at $0.00 | filing |
| 23 Jun 2026filed 25 Jun 2026 | MPLT MapLight TherapeuticsBiotechnology | SEC FORM 4 Code A | —7,864 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —745,875 at $0.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —745,875 at $0.00 | filing |
| 30 Oct 2025filed 30 Oct 2025 | 89biooption or derivative | SEC FORM 4 Code D | —67,700 at $0.00 | filing |
| 30 Oct 2025filed 30 Oct 2025 | 89biooption or derivative | SEC FORM 4 Code D | —56,400 at $0.00 | filing |
| 29 Jul 2025filed 31 Jul 2025 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —662,000 at $0.00 | filing |
| 29 Jul 2025filed 31 Jul 2025 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 12 Jun 2025filed 13 Jun 2025 | PRLD Prelude Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | ALMS AlumisBiotechnology | SEC FORM 4 Bought | $101K15,650 at $6.44 | filing |
| 18 Feb 2025filed 20 Feb 2025 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —523,000 at $0.00 | filing |
| 3 Feb 2025filed 5 Feb 2025 | 89biooption or derivative | SEC FORM 4 Code A | —56,400 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code D | —21,390 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,390 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code D | —380,852 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —380,852 at $0.00 | filing |
News
WAVE Life Sciences (NASDAQ:WVE) and Alumis (NASDAQ:ALMS) Head to Head ComparisonALMS · dailypolitical.com · 18 Oct 2026Alumis Inc.: Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life MeasuresALMS · finanznachrichten.de · 9 Oct 2026
0 headlines in the last 90 days name Martin Babler; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.